Effects of cannabidiol and Δ⁹-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review

References

• Bansal S, Maharao N, Paine MF, Unadkat JD. 2020. Predicting the potential for cannabinoids to precipitate harmacokineticdrug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metab Dispos. 48(10):1008–1017. doi: 10.1124/dmd.120.000073.
   PubMed Web of Science ®Google Scholar
• Bansal S, Paine MF, Unadkat JD. 2022. Comprehensive predictions of cytochrome P450 (P450)-mediated in vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes. Drug Metab Dispos. 50(4):351–360. doi: 10.1124/dmd.121.000734.
   PubMed Web of Science ®Google Scholar
• Bansal S, Zamarripa CA, Spindle TR, Weerts EM, Thummel KE, Vandrey R, Paine MF, Unadkat JD. 2023. Evaluation of cytochrome P450-mediated cannabinoid-drug interactions in healthy adult participants. Clin Pharmacol Ther. 114(3):693–703. doi: 10.1002/cpt.2973.
   PubMed Web of Science ®Google Scholar
• Bardhi K, Coates S, Watson CJW, Lazarus P. 2022. Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy. Expert Rev Clin Phar. 15(12):1443–1460. doi: 10.1080/17512433.2022.2148655.
   PubMed Web of Science ®Google Scholar
• Calhoun SR, Galloway GP, Smith DE. 1998. Abuse potential of dronabinol (Marinol®). J Psychoactive Drugs. 30(2):187–196. doi: 10.1080/02791072.1998.10399689.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. 2017. Clinical ­pharmacology and biopharmaceutics review(s). Application no: 210365Orig1s000; [accessed 2023 Dec 15]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf.
   Google Scholar
• Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V. 2020. Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics. 12(9):846. doi: 10.3390/pharmaceutics12090846.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, Wilfong A, et al. 2018. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 90(14):1207–1209. doi: 10.1212/WNL.0000000000005254.
   Web of Science ®Google Scholar
• Doohan PT, Oldfield LD, Arnold JC, Anderson LL. 2021. Cannabinoid interactions with cytochrome P450 drug metabolism: a full-spectrum characterization. AAPS J. 23(4):91. doi: 10.1208/s12248-021-00616-7.
   PubMed Web of Science ®Google Scholar
• DynaMed. 2023. Cytochrome P450 drug metabolism; [accessed 2023 Dec 1]. https://www.dynamed.com/drug-review/cytochrome-p450-drug-metabolism#GUID-13B09D14-50BB-4283-9B41-7F0A9456080D.
   Google Scholar
• Foster BC, Abramovici H, Harris CS. 2019. Cannabis and cannabinoids: kinetics and interactions. AM J Med. 132(11):1266–1270. doi: 10.1016/j.amjmed.2019.05.017.
   PubMed Web of Science ®Google Scholar
• Geffrey AL, Pollack SF, Bruno PL, Thiele EA. 2015. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 56(8):1246–1251. doi: 10.1111/epi.13060.
   PubMed Web of Science ®Google Scholar
• Gilmartin CGS, Dowd Z, Parker APJ, Harijan P. 2021. Interaction of cannabidiol with other antiseizure medications: a narrative review. Seizure. 86:189–196. doi: 10.1016/j.seizure.2020.09.010.
   PubMed Web of Science ®Google Scholar
• Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. 2022. PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 18(2):e1230.
   PubMedGoogle Scholar
• Han BH, Palamar JJ. 2020. Trends in cannabis use among older adults in the united states, 2015-2018. JAMA Intern Med. 180(4):609–611. doi: 10.1001/jamainternmed.2019.7517.
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. 2001. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology. 155(2):171–179. doi: 10.1007/s002130000657.
   PubMed Web of Science ®Google Scholar
• Jenkins BW, Khokhar JY. 2021. Cannabis use and mental illness: understanding circuit dysfunction through preclinical models. Front Psychiatry. 12:597725. doi: 10.3389/fpsyt.2021.597725.
   PubMed Web of Science ®Google Scholar
• Konefal S, Gabrys R, Porath A. 2022. Clearing the smoke on cannabis. Canadian Centre on Substance Use and Addiction; [accessed 2023 Dec 1]. https://www.ccsa.ca/sites/default/files/2022-05/CCSA-Clearing-the-Smoke-on-Cannabis-Highlights-2022-en_0.pdf.
   Google Scholar
• Lynch T, Price AL. 2007. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Phys. 76(3):391–396.
   PubMed Web of Science ®Google Scholar
• Morrison G, Crockett J, Blakey G, Sommerville K. 2019. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharm Drug Dev. 8(8):1009–1031. doi: 10.1002/cpdd.665.
   PubMed Web of Science ®Google Scholar
• Nasrin S, Watson CJ, Bardhi K, Fort G, Chen G, Lazarus P. 2021. Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites. Drug Metab Dispos. 49(12):1081–1089.
   PubMedGoogle Scholar
• Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. 2021. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metab Dispos. 49(12):1070–1080. doi: 10.1124/dmd.121.000442.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372(71):n71. doi: 10.1136/bmj.n71.
   PubMedGoogle Scholar
• Rasool MF, Rehman AU, Khan I, Latif M, Ahmad I, Shakeel S, Sadiq M, Hayat K, Shah S, Ashraf W, et al. 2023. Assessment of risk factors associated with potential drug-drug interactions among patients suffering from chronic disorders. PLoS One. 18(1):e0276277. doi: 10.1371/journal.pone.0276277.
   PubMed Web of Science ®Google Scholar
• Ridout KK, Young-Wolff KC, Ridout SJA. 2021. Change in blood carbamazepine levels associated with cannabis use. J Clin Psychiatry. 82(3):20cr13777. doi: 10.4088/JCP.20cr13777.
   PubMed Web of Science ®Google Scholar
• Rong C, Carmona NE, Lee YL, Ragguett RM, Pan Z, Rosenblat RD, Subramaniapillai M, Shekotikhina M, Almatham F, Alageel A, et al. 2018. Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents. Expert Opin Drug Saf. 17(1):51–54. doi: 10.1080/14740338.2017.1397128.
   PubMed Web of Science ®Google Scholar
• Roth MD, Marques-Magallanes JA, Yuan M, Sun W, Tashkin DP, Hankinson O. 2001. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and Δ9-tetrahydrocannabinol. Am J Respir Cell Mol Biol. 24(3):339–344. doi: 10.1165/ajrcmb.24.3.4252.
   PubMed Web of Science ®Google Scholar
• Sheikh NK, Dua A. 2023. Cannabinoids. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [accessed 2023 Dec 24]. https://www.ncbi.nlm.nih.gov/books/NBK556062/#.
   Google Scholar
• Simoni-Wastila L, Yang HK. 2006. Psychoactive drug abuse in older adults. Am J Geriatr Pharmacother. 4(4):380–394. doi: 10.1016/j.amjopharm.2006.10.002.
   PubMedGoogle Scholar
• Sinz M, Wallace G, Sahi J. 2008. Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J. 10(2):391–400. doi: 10.1208/s12248-008-9037-4.
   PubMed Web of Science ®Google Scholar
• Smith RT, Gruber SA. 2023. Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions. Front Psychiatry. 13:1055481. doi: 10.3389/fpsyt.2022.1055481.
   PubMed Web of Science ®Google Scholar
• Taeho GR, Rosenheck RA. 2023. Increasing use of cannabis for medical purposes among U.S. residents, 2013–2020. Am J Prev Med. 65(3):528–533.
   PubMed Web of Science ®Google Scholar
• Thai C, Tayo B, Critchley D. 2021. A phase 1 open-label, fixed-sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin Pharm Drug Dev. 10(11):1279–1289. doi: 10.1002/cpdd.950.
   PubMed Web of Science ®Google Scholar
• Ujváry I, Hanuš L. 2016. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 1(1):90–101. doi: 10.1089/can.2015.0012.
   PubMedGoogle Scholar
• [US FDA] U.S. Food and Drug Administration. 2018. Highlights of prescribing information; [accessed 2023 Dec 15]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
   Google Scholar
• Vaughn S, Strawn J, Poweleit E, Sarangdhar M, Ramsey LB. 2021. The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations. JPM. 11(7):615. doi: 10.3390/jpm11070615.
   Google Scholar
• Vermersch P. 2011. Sativex ® (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Expert Rev Neurother. 11(sup4):15–19. doi: 10.1586/ern.11.27.
   PubMedGoogle Scholar
• Yamaori S, Kinugasa Y, Jiang R, Takeda S, Yamamoto I, Watanabe K. 2015. Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Life Sci. 136:87–93. doi: 10.1016/j.lfs.2015.07.007.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141. doi: 10.1016/j.pharmthera.2012.12.007.
   PubMed Web of Science ®Google Scholar
• Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, et al. 2021. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 22(23):12808. doi: 10.3390/ijms222312808.
   PubMed Web of Science ®Google Scholar